[포스닥 연구원 모집]
등록일 Oct 22,2021 |
Looking for a postdoctoral fellow
Introduction to Kim Lab:
The Kim Lab at Columbia University Irving Medical Center focuses on translational cancer and vascular biology with a goal of identifying mechanisms underlying the contribution of vascular abnormalities to 1) tumor immunosuppression; and 2) resistance to immunotherapies in the treatment of advanced cancer.
The Kim Lab is looking for a postdoctoral fellow who will work with on preclinical and translational studies based on various mouse tumor models and human specimens by using tools such as followings:
• Immune profiling using flow cytometry or multiplex staining.
• Single cell sequencing and analysis of tumors isolated from mice
• Identification of vascular changes in mouse and human tissues using imaging system
These are experience preferred but not required.
Additional preferred qualifications of research area:
• Experience in neurodegenerative diseases
• Experience in cancer biology using mouse models
• Experience in cancer immunology
Please send your cover letter and CV to email@example.com if you are interested in the position. We will contact potential candidates for following interview process after our
Blood vessels undergo rapid functional and structural changes called angiogenesis and vascular remodeling in many malignant disorders. Although previous genetic and molecular studies have identified the significance of vascular changes in pathologic conditions including cancer, major challenges are 1) to efficiently target vascular changes in tumor microenvironment during tumor progression, leading to effective anti-tumor and anti-metastatic effects and 2) to determine a potential interplay between the vascular changes and immune system in cancer.
We are currently examining two inter-related topics:
1. To understand the significance of vascular niche on promoting distant metastasis in pancreatic neuroendocrine tumors in relation to anti-VEGF therapy resistance.
2. To identify the molecular mechanisms by which vascular abnormalities regulate immunosuppression and resistance to immunotherapy in cancer.
By using an integrated approach that combines cell biology with preclinical studies utilizing a genetically engineered mouse tumor model along with translational studies, our study will provide paths forward for the development of new therapeutic targets and of better therapeutic strategies in cancer promoting vascular normalization and effective anti-tumor effects.